How Makary’s FDA is embracing a more skeptical view of vaccines

Makary seems just as willing as RFK Jr. to use his power and position to more harshly scrutinize vaccines and to shift vaccination policy.

April 29, 2025 Check out STAT+

Sponsored By

Andrew Harnik/Getty Images STAT+ | How Marty Makary's FDA is embracing a more skeptical view of vaccines FDA vaccine oversight is shifting under RFK Jr. and Marty Makary, with increased scrutiny, mixed messaging, and growing concerns among health experts. By Lizzy Lawrence STAT+ | The end of compounded GLP-1 copies leaves many patients in a 'lose-lose' position Thousands face uncertainty as compounded GLP-1s disappear, struggling to afford care and navigate sudden changes in obesity and diabetes treatment. By Katie Palmer and Elaine Chen STAT+ | Amid FDA chaos, approval of a rare disease drug gets delayed — again "In my opinion, this is because of the chaos and lack of resources," said a former FDA official familiar with the matter. By Ed Silverman OLIVER CONTRERAS/AFP via Getty Images With one month to go, few details on RFK Jr.'s MAHA commission  With a May 24 deadline looming, Kennedy's MAHA commission has held just one full meeting on its goal of reducing childhood chronic disease. By Isabella Cueto STAT+ | Pharma's reputation with patient groups dips again, mostly due to pricing issues Just 14% of the patient groups reported that drug companies had "excellent" or "good" reputations for fair pricing. By Ed Silverman STAT+ | Novo Nordisk strikes telehealth deals for obesity drug, following Eli Lilly The move could help Novo Nordisk expand the direct-to-consumer market for Wegovy, as it also seeks to fend off competition from compounders. By Elaine Chen Win McNamee/Getty Images Opinion: The future of preventive care depends on the Supreme Court's reading of two words The issues at stake in Braidwood extend beyond the ACA itself, delving into fundamental constitutional law and the separation of powers questions. By Richard Hughes IV Opinion: Medicare regulations hamper providers without helping patients Medicare's quality-based payment incentives divert physicians' attention from patients' most pressing needs and increase the administrative burden. By David Howard

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser